NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
Clinical Trials
7 trialsNCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT02538471 2019-12-09
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01403610 2019-07-24
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT01893879 2017-05-18
PCTTPL
Stanford University
Phase NA Terminated